PER2 Antibody - BSA Free

Western Blot: PER2 AntibodyAzide and BSA Free [NBP2-93587]

Western Blot: PER2 Antibody [NBP2-93587] - Analysis of extracts of Mouse liver, using PER2 antibody at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit. Exposure time: 90s.

Immunohistochemistry-Paraffin: PER2 Antibody - Azide and BSA Free [NBP2-93587]

Immunohistochemistry-Paraffin: PER2 Antibody [NBP2-93587] - Rat spleen using PER2 Rabbit pAb at dilution of 1:100 (40x lens).

Immunohistochemistry-Paraffin: PER2 Antibody - Azide and BSA Free [NBP2-93587]

Immunohistochemistry-Paraffin: PER2 Antibody [NBP2-93587] - Human thyroid cancer using PER2 Rabbit pAb at dilution of 1:100 (40x lens).

Immunohistochemistry-Frozen: Rabbit Polyclonal PER2 Antibody [NBP2-93587] -

Immunohistochemistry-Frozen: Rabbit Polyclonal PER2 Antibody [NBP2-93587] - 10X magnification. Immunoreactive cell bodies (DAB staining) along the 4th ventricle in 20um from Hyla cinerea. Image from a verified customer review.

Western Blot: PER2 Antibody - BSA Free [NBP2-93587] -

Circadian gene expression varies between pHGGs and pLGGs. (A) Interleaved scatter plots represent bulk RNA sequencing (rsem FPKM) analysis comparing circadian gene expression across pediatric low-grade glioma (pLGG, n = 426, blue) and pediatric high-grade glioma (pHGG, n = 211, red) samples from the Pediatric Brain Tumor Atlas (PBTA, Provisional). Data are expressed as mean +/- SEM, and expression values are log₂-transformed FPKM counts. Statistical analysis was performed using a two-way ANOVA with Benjamini and Hochberg false discovery rate (FDR) to determine differences in gene expression between pHGGs and pLGGs. Each dot represents an individual tumor sample. Asterisks indicate statistically significant differences (*P < 0.05), while “NS" denotes non-significant comparisons. (B) Western blots of four representative pediatric high-grade glioma tissue samples (left) and four pediatric low-grade glioma tissue samples (right) comparing BMAL1, CLOCK, PER2, and REV-ERB alpha protein expression (sections of separate blots displayed; full blots are shown in Supplementary Figure S3). Of note, tissue sample HGG 3 is derived from the same patient as the STN-49 cell line. (C) Normalization to beta-ACTIN control reveals BMAL1 (p < 0.05, 1.57 vs. 0.98) and CLOCK (p < 0.05, 0.98 vs. 0.39) protein expression is higher in high-grade gliomas compared to low-grade gliomas, REV-ERB alpha is lower (p < 0.05, 0.12 vs. 0.55), and there are no significant differences in PER2 protein expression. Data are expressed as mean +/- SEM. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41598-025-17461-9), licensed under a CC-BY license. Not internally tested by Novus Biologicals.